Actinium Pharmaceuticals
ATNM
39 hedge funds and large institutions have $6.63M invested in Actinium Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 17 closing their positions.
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
2.77% less ownership
Funds ownership: 9.27% → 6.5% (-2.8%)
7% less funds holding
Funds holding: 42 → 39 (-3)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
43% less call options, than puts
Call options by funds: $151K | Put options by funds: $265K
45% less capital inflows, than outflows
Capital inflows: $2.51M | Capital outflows: $4.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$463K |
| 2 |
Goldman Sachs
New York
|
+$394K |
| 3 |
Bridgeway Capital Management
Houston,
Texas
|
+$324K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$171K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock Fund Advisors
San Francisco,
California
|
-$1.58M |
| 2 |
State Street
Boston,
Massachusetts
|
-$769K |
| 3 |
BlackRock Institutional Trust
San Francisco,
California
|
-$493K |
| 4 |
Bank of New York Mellon
New York
|
-$425K |
| 5 |
Renaissance Technologies
New York
|
-$234K |
ATNM Hedge Fund Activity: Q2 2015 in Review
39 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2015, worth a combined $6.63M — down 20% from $8.25M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ATNM and 14 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 10 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $463K. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.58M.
- 39 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2015, down from 42 in Q1 2015.
- Funds reported $6.63M of Actinium Pharmaceuticals stock for Q2 2015, down 20% quarter-over-quarter.
- 14 funds opened new Actinium Pharmaceuticals positions in Q2 2015 and 17 closed out, a net change of -3 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2015 was Millennium Management, an estimated $463K added.
- The largest Actinium Pharmaceuticals seller in Q2 2015 was BlackRock Fund Advisors, an estimated $1.58M sold.
Based on aggregated 13F filings for Q2 2015.